Literature DB >> 11850728

Molecular mechanisms for the regulation of penile smooth muscle contractility.

I Sáenz de Tejada1.   

Abstract

Relaxation of penile smooth muscle (arterial and trabecular) initiates and maintains penile erection. Relaxation of smooth muscle is viewed as a 'resetting' of contractile machinery by resumption of a precontractile state accomplished by lowering cytosolic Ca(+2) and/or by a decrease in sensitivity of the contractile machinery to Ca(+2). There are various mechanisms whereby cytosolic Ca(+2) can be reduced and relaxation achieved, but in general, all pathways depend on the accumulation of the nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) or activation of K channels with hyperpolarization. Another mechanism, activation of Na(+)/K(+) adenosine triphosphatase (ATPase) by nitric oxide, has been shown to be involved in relaxation of trabecular smooth muscle. Since Na(+)/K(+) ATPase is electrogenic, its stimulation would cause hyperpolarization. Hyperpolarization will prevent the opening of voltage-dependent calcium channels. Guanylate cyclase, which catalyzes the conversion of guanosine triphosphate to cGMP, is activated by nitric oxide. cGMP activates protein kinase G, which through multiple phosphorylations facilitates calcium sequestration and reduces the entry of calcium into the cell. Other muscle relaxants act by way of a cAMP-dependent mechanism such as prostaglandin E, vasoactive intestinal polypeptide, and catecholamines (via beta-receptors). These substances react with membrane receptors coupled to a GS-type protein that stimulates adenylate cyclase, which catalyzes the accumulation of cAMP. DOI: 10.1038/sj/ijir/3900790

Entities:  

Mesh:

Year:  2002        PMID: 11850728     DOI: 10.1038/sj.ijir.3900790

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  8 in total

Review 1.  Androgens are fundamental in the maintenance of male sexual health.

Authors:  Alvaro Morales
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 2.  Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Alberto Briganti; Andrea Salonia; Federico Deho'; Giuseppe Zanni; Luigi Barbieri; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

Review 3.  Emerging tools for erectile dysfunction: a role for regenerative medicine.

Authors:  Lukman Hakim; Frank Van der Aa; Trinity J Bivalacqua; Petter Hedlund; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2012-07-24       Impact factor: 14.432

Review 4.  Causes of erectile dysfunction.

Authors:  Jeremy P W Heaton; Michael A Adams
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 5.  Erectile dysfunction as a cardiovascular risk factor in patients with diabetes.

Authors:  Giorgio Gandaglia; Andrea Salonia; Niccolò Passoni; Piero Montorsi; Alberto Briganti; Francesco Montorsi
Journal:  Endocrine       Date:  2012-09-05       Impact factor: 3.633

Review 6.  Vasoconstriction and vasodilation in erectile physiology.

Authors:  Thomas M Mills
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

Review 7.  Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review.

Authors:  James Anaissie; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2016-08-03

8.  On the pathogenesis of penile venous leakage: role of the tunica albuginea.

Authors:  Ahmed Shafik; Ismail Shafik; Olfat El Sibai; Ali A Shafik
Journal:  BMC Urol       Date:  2007-09-05       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.